Effect of metformin on the human T98G glioblastoma multiforme cell line

Experimental and Therapeutic Medicine

Volumn 7, Issue 5, 2014, Pages 1285-1290

  Ucbek, Ali ^a   Özünal, Zeynep Güneş ^b   Uzun, Özge ^a   Gepd, Akçahaniremen ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Glioblastoma cell line; Metformin; T98G

Indexed keywords

3 (4, 5 DIMETHYL 2 THIAZOLYL) 2, 5 DIPHENYLTETRAZOLIUM BROMIDE; ACRIDINE ORANGE; CASPASE 3; DNA NUCLEOTIDYLEXOTRANSFERASE; ETHIDIUM BROMIDE; METFORMIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MTT ASSAY; NICK END LABELING; TUMOR CELL LINE;

EID: 84896838154     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1597     Document Type: Article

References (29)

1. Campbell IW: Metformin-life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007. (Meeting Report). Br J Diabet Vasc Dis 7: 247-252, 2007.
2. Li J, Deng J, Sheng W and Zuo Z: Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101: 564-574, 2012.
3. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT and TsaiHN: Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord 18: 753-758, 2012.
4. Gallagher EJ and LeRoith D: Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann NY Acad Sci 1243: 54-68, 2011.
5. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625, 2009.
6. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
7. Zhuang Y and Miskimins WK: Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 9: 603-615, 2011.
8. Will MA, Palaniappan M, Peegel H, Kayampilly P and MenonKM: Metformin: direct inhibition of rat ovarian theca-interstitial cell proliferation. Fertil Steril 98: 207-214, 2012.
9. Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH and VenkateswaranV: Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis15: 346-352, 2012.
10. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-MelodyJ, etal: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.
11. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, DepinhoRA, Montminy M and Cantley LC: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646, 2005.
12. Ben Sahra I, Regazzetti C, Robert G, Laurent K, LeMarchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-PeraldiS and Bost F: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71: 4366-4372, 2011.
13. Zhuang Y and Miskimins WK: Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3: 18, 2008.
14. Peacock KH and Lesser GJ: Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol 7: 479-489, 2006.
15. Zhou J, Atsina KB, Himes BT, Strohbehn GW and SaltzmanWM: Novel delivery strategies for glioblastoma. Cancer J 18: 89-99, 2012.
16. Krakstad C and Chekenya M: Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9: 135, 2010.
17. Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S and Okopień B: Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 62: 956-965, 2010.
18. Ferreira CG, Epping M, Kruyt FA and Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res 8: 2024-2034, 2002.
19. Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987.
20. Muppidi J, Porter M and Siegel RM. Measurement of apoptosis and other forms of cell death. Curr Protoc Immunol Chapter 3: Unit 3.17, 2004.
21. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092-1099, 2010.
22. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO and de Vries EG.: Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380, 2010.
23. Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71: 3196-3201, 2010.
24. Janjetovic K, Vucicevic L, Misirkic M, VilimanovichU, TovilovicG, Zogovic N, etal: Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of AKT. Eur J Pharmacol 651: 41-50, 2011.
25. Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity invivo. Neoplasia 13: 483-491, 2011.
26. Isakovic A, Harhaji L, Stevanovic D, MarkovicZ, Sumarac-Dumanovic M, Starcevic V, Micic D and TrajkovicV: Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 64: 1290-1302, 2007.
27. Vucicevic L, Misirkic M, Janjetovic K, Harhaji-TrajkovicL, PricaM, Stevanovic D, Isenovic E, SudarE, Sumarac-DumanovicM, MicicD and TrajkovicV: AMP-activated protein kinase-dependent and-independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol 77: 1684-1693, 2009.
28. Kraskstad C and Chekenya M: Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9: 135, 2010.
29. Mao H, Lebrun DG, Yang J, Zhu VF and Li M: Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest 30: 48-56, 2012.